Terry M Therneau

List of Publications by Year
in descending order

99 papers	5,615 citations	94433 37 h-index	85541 71 g-index
101 all docs	101 docs citations	101 times ranked	8322 citing authors

#	Article	IF	Citations
1	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.8	581
2	Longitudinal tau PET in ageing and Alzheimer's disease. Brain, 2018, 141, 1517-1528.	7.6	309
3	Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study. Lancet Neurology, The, 2017, 16, 435-444.	10.2	241
4	Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year community study. Hepatology, 2018, 67, 1726-1736.	7.3	239
5	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223
6	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain, 2018, 141, 271-287.	7.6	218
7	Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology, 1999, 29, 644-647.	7.3	209
8	Assessing calibration of prognostic risk scores. Statistical Methods in Medical Research, 2016, 25, 1692-1706.	1.5	200
9	Prevalence of Multimorbidity in a Geographically Defined American Population. Mayo Clinic Proceedings, 2014, 89, 1336-1349.	3.0	193
10	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
11	The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – A longitudinal cohort study. Journal of Hepatology, 2019, 71, 1229-1236.	3.7	181
12	Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. BMJ Open, 2015, 5, e006413-e006413.	1.9	180
13	Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology, 1998, 27, 1220-1226.	7.3	150
14	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
15	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurology, The, 2016, 15, 56-64.	10.2	104
16	Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology, 1998, 28, 33-38.	7.3	100
17	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. Mayo Clinic Proceedings, 2012, 87, 1071-1079.	3.0	94
18	Iron overload in cirrhosis?HFE genotypes and outcome after liver transplantation. Hepatology, 2000, 31, 456-460.	7.3	93

#	Article	IF	Citations
19	Aspirin use and the risk of cholangiocarcinomaâ€¡. Hepatology, 2016, 64, 785-796.	7.3	84
20	A New Clinically Based Staging System for Perihilar Cholangiocarcinoma. American Journal of Gastroenterology, 2014, 109, 1881-1890.	0.4	80
21	BIMA V3: an aligner customized for mate pair library sequencing. Bioinformatics, 2014, 30, 1627-1629.	4.1	80
22	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
23	Measure of Functional Independence Dominates Discharge Outcome Prediction After Inpatient Rehabilitation for Stroke. Stroke, 2015, 46, 1038-1044.	2.0	73
24	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	7.6	68
25	Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?. Journal of Rheumatology, 2017, 44, 732-739.	2.0	67
26	The Role of Threeâ€Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery. Hepatology, 2020, 71, 510-521.	7.3	65
27	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	4.2	63
28	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.1	62
29	Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. PLoS ONE, 2015, 10, e0138347.	2.5	62
30	Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. Clinical Gastroenterology and Hepatology, 2021, 19, 1915-1924.e6.	4.4	57
31	Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records. Journal of Biomedical Informatics, 2020, 102, 103364.	4.3	56
32	Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. British Journal of Haematology, 1999, 104, 131-137.	2.5	55
33	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer Journal, 2018, 8, 96.	6.2	47
34	Extending Association Rule Summarization Techniques to Assess Risk of Diabetes Mellitus. IEEE Transactions on Knowledge and Data Engineering, 2015, 27, 130-141.	5.7	44
35	Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. Clinical Gastroenterology and Hepatology, 2022, 20, 1374-1381.e6.	4.4	43
36	Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. European Radiology, 2019, 29, 5823-5831.	4.5	40

#	ARTICLE	IF	CITATIONS
37	Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transplantation, 2017, 23, 733-740.	2.4	39
38	Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. Clinical Colorectal Cancer, 2017, 16, 115-123.e3.	2.3	38
39	Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population. International Journal of Cardiology, 2017, 240, 379-385.	1.7	37
40	Application of multi-state models in cancer clinical trials. Clinical Trials, 2018, 15, 489-498.	1.6	36
41	Global transcriptional profiling using RNA sequencing and DNA methylation patterns in highly enriched mesenchymal cells from young versus elderly women. Bone, 2015, 76, 49-57.	2.9	34
42	Metformin does not improve survival in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 15750.	3.3	33
43	Predicting Progression to Mild Cognitive Impairment. Annals of Neurology, 2019, 85, 155-160.	5.3	32
44	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	5.3	31
45	Fifty-Year Incidence of WaldenstrÃ¶m Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clinic Proceedings, 2018, 93, 739-746.	3.0	29
46	Analysis of timeâ€toâ€event for observational studies: Guidance to the use of intensity models. Statistics in Medicine, 2021, 40, 185-211.	1.6	29
47	Comparative Effectiveness of Carotid Revascularization Therapies. Stroke, 2014, 45, 3311-3319.	2.0	28
48	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	3.1	27
49	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	9.0	27
50	Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations. Clinical Trials, 2020, 17, 285-294.	1.6	25
51	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	4.2	24
52	What Does PLIER Really Do?. Cancer Informatics, 2008, 6, 117693510800600.	1.9	23
53	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Liver Cancer, 2017, 6, 126-136.	7.7	23
54	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22

#	Article	IF	Citations
55	Using machine learning to improve the accuracy of patient deterioration predictions: Mayo Clinic Early Warning Score (MC-EWS). Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1207-1215.	4.4	22
56	Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 181-187.	2.0	20
57	What does PLIER really do?. Cancer Informatics, 2008, 6, 423-31.	1.9	19
58	Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 1815-1825.	1.9	16
59	Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World Journal of Gastroenterology, 2018, 24, 1321-1331.	3.3	16
60	Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology, 2023, 77, 268-274.	7.3	16
61	Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma. Hepatology, 2020, 72, 1298-1309.	7.3	15
62	Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	4.2	15
63	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Medicine, 2018, 7, 5870-5878.	2.8	14
64	Longitudinal cohorts for harnessing the electronic health record for disease prediction in a US population. BMJ Open, 2021, 11, e044353.	1.9	14
65	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	3.3	12
66	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. Blood Cancer Journal, 2019, 9, 49.	6.2	11
67	BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. Hpb, 2021, 23, 762-769.	0.3	11
68	Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis. European Radiology, 2022, 32, 950-958.	4.5	11
69	Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. Cancer Medicine, 2015, 4, 1599-1602.	2.8	9
70	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. Scientific Reports, 2018, 8, 7421.	3.3	9
71	Sharpening spots: correcting for bleedover in cDNA array images. Mathematical Biosciences, 2002, 176, 1-15.	1.9	8
72	The impact of arm lymphedema on healthcare utilization during long-term breast cancer survivorship: a population-based cohort study. Journal of Cancer Survivorship, 2020, 14, 347-355.	2.9	8

#	Article	IF	Citations
73	MELDing the Lille Score to More Accurately Predict Mortality in Alcoholic Hepatitis. Gastroenterology, 2015, 149, 281-283.	1.3	7
74	Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. Mayo Clinic Proceedings, 2019, 94, 27-36.	3.0	7
75	A Prospective Study of CD38/45 Flow Cytometry and Immunofluorescence Microscopy to Detect Blood Plasma Cells in Patients with Plasma Cell Proliferative Disorders. Leukemia and Lymphoma, 2000, 38, 345-350.	1.3	6
76	Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. Clinical Immunology, 2020, 211, 108342.	3.2	6
77	A Topic-modeling Based Framework for Drug-drug Interaction Classification from Biomedical Text. AMIA ... Annual Symposium proceedings, 2016, 2016, 789-798.	0.2	6
78	Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. Medical and Pediatric Oncology, 1989, 17, 79-82.	1.0	5
79	DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry. , 1996, 26, 253-259.		5
80	Prognostic Value of Model for End-Stage Liver Disease Score Measurements on a Daily Basis in Critically Ill Patients With Cirrhosis. Mayo Clinic Proceedings, 2015, 90, 1196-1206.	3.0	5
81	Aspirin, Statins, Non-aspirin NSAIDs, Metformin, and the Risk of Biliary Cancer: A Swedish Population-Based Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 804-810.	2.5	5
82	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer Journal, 2020, 10, 39.	6.2	4
83	Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation. BMC Cancer, 2022, 22, 221.	2.6	4
84	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	3.1	4
85	The impact of pharmacokinetic gene profiles across human cancers. BMC Cancer, 2018, 18, 577.	2.6	3
86	Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. Journal of the Neurological Sciences, 2020, 411, 116687.	0.6	3
87	Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1577-1581.	1.4	3
88	Optimal Two-Stage Screening Designs for Survival Comparisons. Biometrika, 1990, 77, 507.	2.4	3
89	Reply:. Hepatology, 2008, 48, 688-688.	7.3	2
90	Cognitive function and neuropathological outcomes: a forward-looking approach. Journal of Neurology, 2019, 266, 2920-2928.	3.6	2

#	Article	IF	Citations
91	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. Blood, 2005, 106, 5080-5080.	1.4	1
92	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. Blood, 2006, 108, 3493-3493.	1.4	1
93	Memories of Sam Wieand. Lifetime Data Analysis, 2008, 14, 13-15.	0.9	0
94	Reply to: â€œChronic kidney disease after liver transplantationâ€• Journal of Hepatology, 2015, 62, 244-245.	3.7	0
95	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.. Blood, 2008, 112, 1672-1672.	1.4	0
96	Comparative Analysis of Staging Systems in AL Amyloidosis. Blood, 2018, 132, 3228-3228.	1.4	0
97	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. Blood, 2018, 132, 4458-4458.	1.4	0
98	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. Blood, 2019, 134, 4362-4362.	1.4	0
99	Response to â€œOn the reproducibility of quantitative susceptibility mapping and its potential as a clinical biomarker: A comment on Cogswell etÂal. 2021â€• NeuroImage, 2022, 251, 118992.	4.2	0